Oncolytics Biotech Inc.
TTSX:ONCShare Statistics
As of June 30, 2025, Oncolytics Biotech Inc. has 97.41M shares outstanding.
| Shares Outstanding | 97.41M |
Valuation Ratios
These figures are as of June 30, 2025.
| PB Ratio | -2.22 |
| P/TBV Ratio | 14.38 |
| P/FCF Ratio | -3.56 |
| P/OCF Ratio | -3.55 |
Financial Position
As of June 30, 2025, Oncolytics Biotech Inc. maintains a current ratio of 2.88, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.88 |
| Quick Ratio | 2.24 |
| Debt / Equity | 14.58 |
| Debt / EBITDA | -0.03 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -116.87, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -116.87 |
Dividends & Yields
These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -28.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.47, meaning Oncolytics Biotech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -16.47 |
| FCF Yield | -28.10 |
Stock Splits
Oncolytics Biotech Inc.'s most recent stock split took place on May 25, 2018 with a 200:21 split ratio.
| Last Split Date | 5/25/2018 |
| Split Ratio | 200:21 |
Scores
As of June 30, 2025, Oncolytics Biotech Inc. has an Altman Z-Score of -34.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -34.99 |